OBiO Technology
OBiO Technology is a Shanghai-based, privately held provider of viral-based gene therapy CRO and CDMO/CMO services, founded in 2013 to serve biotech and pharmaceutical sponsors developing gene therapies through research, process development, and GMP manufacturing.
- Company typePrivate
- Founded2013
- HeadquartersShanghai, China
- Headcount251–500
- GTM typeB2B
- OfferingServices
OBiO Technology firmographics
Firmographics- Name
- OBiO Technology
- Website
- https://obiosh.com
- Company type
- Private
- Founded year
- 2013
- Operating status
- Operating
- Headcount range
- 251–500 employees
- Short description
- OBiO Technology is a Shanghai-based, privately held provider of viral-based gene therapy CRO and CDMO/CMO services, founded in 2013 to serve biotech and pharmaceutical sponsors developing gene therapies through research, process development, and GMP manufacturing.
- Ownership category
- akta.pro rank
OBiO Technology industry classification
Industry- Product category
- Gene Therapy CDMO Services
- NAICS
- Scientific Research and Development Services (5417), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Gene Therapy CDMO (Viral Vector Manufacturing) (HLAGAGAB)
- akta.pro secondary industries
- Gene Therapy (Viral Vector/Plasmid) CDMO (HLAGABAE), Patient Recruitment, Site Feasibility & Trial Enablement CROs (HLAGAAAI), Gene Therapy Regulatory, Pharmacovigilance & Clinical Operations Services (HLAAACAM)
Keywords
Where OBiO Technology is headquartered
LocationHeadquarters
- HQ city
- Shanghai
- HQ country
- China
- HQ region
- Asia
Markets served
OBiO Technology business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Technology or R&D, Infrastructure
OBiO Technology product offering
Product offeringCore offering
OBiO Technology provides outsourced contract research (CRO) and contract development and manufacturing (CDMO/CMO) services focused on viral vector-based gene therapy. Offerings cover preclinical research support, viral vector process development, and GMP-grade manufacturing for gene therapy developers. The company delivers these as integrated service engagements rather than off-the-shelf products.
Differentiator
Problem solved
Functional benefit
Products and services
- Viral-Based Gene Therapy CRO Services
Companies that use OBiO Technology
Customer profileIdeal customer profiles1 record
OBiO Technology technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
OBiO Technology competitors and assessment
Company assessmentDirect peers
- WuXi Advanced Therapies Unit (WuXi AppTec): Largest China-based gene therapy CDMO offering viral vector manufacturing and integrated development services. Direct competitor for OBiO across both domestic Chinese gene therapy developers and global clients seeking China-based manufacturing.
- GenScript ProBio: CDMO arm of GenScript offering viral vector, cell therapy, and plasmid manufacturing with global reach. Competes head-to-head with OBiO for gene therapy CRO/CDMO contracts from Chinese and Asia-Pacific sponsors.
- Yposkesi: Europe-based CDMO specialized in AAV and lentiviral vector manufacturing for gene therapy. Comparable service offering to OBiO with similar focus on viral vector production for clinical-stage gene therapy developers.
- Aldevron: Specialized manufacturer of plasmids, mRNA, and proteins used in gene therapy production. Provides upstream raw materials into the gene therapy value chain that overlaps with OBiO's CDMO customer base.
Broad incumbents
- AGC Biologics: Global CDMO with dedicated gene therapy/viral vector manufacturing capacity across multiple sites. Competes with OBiO for international gene therapy sponsors seeking commercial-scale viral vector supply.
- Catalent (Paragon Gene Therapy): Large global CDMO with significant viral vector and gene therapy manufacturing capabilities acquired via Paragon. Represents the scaled incumbent alternative OBiO must differentiate against for late-stage contracts.
- Lonza: Global CDMO leader with expanding cell and gene therapy services including viral vector manufacturing. Sets the competitive benchmark for scale, quality systems, and breadth that OBiO must match.
- Bioreliance (MilliporeSigma / Merck KGaA BioReliance): Global bioservices CDMO offering viral vector manufacturing, biosafety testing, and cell banking for gene therapy. Competes with OBiO for both manufacturing slots and ancillary testing services.
- Cobra Biologics (Charles River Laboratories): CDMO providing viral vector and plasmid DNA manufacturing for gene therapy and viral vaccine clients. Direct alternative for sponsors comparing OBiO against established European CDMOs.
- Thermo Fisher Scientific (Patheon Viral Vector Services): Diversified life sciences giant offering viral vector development and manufacturing through its CDMO services. Sets the high-water mark for integrated CRO-to-CDMO scale against which OBiO competes.
Market position
Customer concentration
OBiO Technology social profiles
Digital presenceOBiO Technology financial estimates
Financial estimateRevenue estimate
Valuation estimate
OBiO Technology leadership team
Management profileNumber of profiles
Profiles2 records
OBiO Technology funding detail
Funding detailFunding overview
Funding rounds2 records
Investors9 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
OBiO Technology M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about OBiO Technology
What does OBiO Technology do?
OBiO Technology provides outsourced contract research (CRO) and contract development and manufacturing (CDMO/CMO) services focused on viral vector-based gene therapy. Offerings cover preclinical research support, viral vector process development, and GMP-grade manufacturing for gene therapy developers. The company delivers these as integrated service engagements rather than off-the-shelf products.
When was OBiO Technology founded?
OBiO Technology was founded in 2013. It employs 251 to 500 people.
Where is OBiO Technology based?
OBiO Technology is headquartered in Shanghai, China, in the Asia region.
Who are OBiO Technology's main competitors?
Direct peers on record are WuXi Advanced Therapies Unit (WuXi AppTec), GenScript ProBio, Yposkesi and Aldevron. Broad incumbents are AGC Biologics, Catalent (Paragon Gene Therapy), Lonza, Bioreliance (MilliporeSigma / Merck KGaA BioReliance), Cobra Biologics (Charles River Laboratories) and Thermo Fisher Scientific (Patheon Viral Vector Services).
Does OBiO Technology have an API?
No public API is recorded for OBiO Technology.
What industry is OBiO Technology in?
OBiO Technology's product category is Gene Therapy CDMO Services. Its primary akta.pro industry code is HLAGAGAB, Gene Therapy CDMO (Viral Vector Manufacturing), with a secondary code of HLAGABAE, Gene Therapy (Viral Vector/Plasmid) CDMO. Its NAICS code is 5417 and its SIC code is 8731.